Nkarta reports Q2 2021 net loss $21.5M; cash runway into 2H 2023; NKX101 data by year-end

Nkarta, Inc.

2022-Q2 EPS reported -$1.25

Net loss $21.5M ($0.66/share) for Q2 2021; R&D expenses $16.0M, G&A $5.7M.
Cash, equivalents, restricted cash, and short-term investments $280.3M as of June 30, 2021.
Initial Phase 1 data for NKX101 (CD33-targeted NK cell therapy) expected by end of 2021.
NKX019 (CD19-targeted NK) Phase 1 patient dosing expected to start in 2H 2021.
Collaboration with CRISPR Therapeutics to co-develop two CAR-NK candidates and license CRISPR/Cas9 gene editing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.